Print Page | Sign In | Join
News & Press
Filter news by category:

Read about recent events, essential information and the latest community news.

Displaying page 6 of 27
1  |  2  |  3  |  4  |  5  |  6  |  7  |  8  |  9  |  10  |  11  >   >>   >| 

Scientific Advancements
Friday, November 17, 2023   (0 Comments - view/add)
Medtronic launches new frontier to treat high blood pressure »
Medtronic launching a new frontier in treating high blood pressure FDA approves medical device-related hypertension t...
Tuesday, November 14, 2023   (0 Comments - view/add)
Vy Spine Announces FDA Clearance for its ClariVy OsteoVy PEKK Cervical IBF »
Vy Spine Announces FDA Clearance for its ClariVy OsteoVy PEKK Cervical IBF November 14, 2023 01:05 PM Eastern Standar...
Thursday, November 2, 2023   (0 Comments - view/add)
INSIGHTEC ANNOUNCES NEW CATEGORY I CPT® CODE FROM AMA FOR NEURO PROCEDURES U »
INSIGHTEC ANNOUNCES NEW CATEGORY I CPT® CODE FROM AMA FOR NEURO PROCEDURES USING MR-GUIDED FOCUSED ULTRASOUND New cod...
Thursday, November 2, 2023   (0 Comments - view/add)
Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE® »
Catalyst Pharmaceuticals Receives Two New U.S. Patent Allowances For FIRDAPSE® New Patents Further Reinforce the FIR...
Thursday, November 2, 2023   (0 Comments - view/add)
New Clinical Data on OPKO Health’s RAYALDEE® (ER Calcifediol) Presented at Kidney Week 2023 »
New Clinical Data on OPKO Health’s RAYALDEE® (ER Calcifediol) Presented at Kidney Week 2023 November 02, 2023 10:00 E...
Wednesday, November 1, 2023   (0 Comments - view/add)
Wednesday, November 1, 2023   (0 Comments - view/add)
ZyVersa Therapeutics Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating »
ZyVersa Therapeutics Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating That Inflammasome ASC...
Tuesday, October 31, 2023   (0 Comments - view/add)
Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder »
Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Effica...
Monday, October 30, 2023   (0 Comments - view/add)
Transpire Bio Expands Access and Innovation in Inhalation Therapies with New Research and Manufactur »
Transpire Bio Expands Access and Innovation in Inhalation Therapies with New Research and Manufacturing Facility...
Thursday, October 26, 2023   (0 Comments - view/add)
Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrop »
Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE® (vamorolone) for Duchenne Muscular Dystrophy Granted to Santhera...
Tuesday, October 24, 2023   (0 Comments - view/add)
Longeveron Inc. Featured in Syndicated Broadcast Highlighting Top-Line Results from CLEAR MIND Phase »
Longeveron Inc. Featured in Syndicated Broadcast Highlighting Top-Line Results from CLEAR MIND Phase 2a Clinical Trial of...
Tuesday, October 24, 2023   (0 Comments - view/add)
Germfree Laboratories and Title21 Health Solutions Transform Cell and Gene Therapy Manufacturing wit »
Germfree Laboratories and Title21 Health Solutions Transform Cell and Gene Therapy Manufacturing with Decentralized Innova...
Tuesday, October 17, 2023   (0 Comments - view/add)
VySpine Announces FDA Clearances for VySpan, VyLam and VySpine Innovations »
VySpine Announces FDA Clearances for VySpan, VyLam and VySpine Innovations Trio of Clearances Expands VySpine’s Grow...
Friday, October 13, 2023   (0 Comments - view/add)
Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDA »
Catalyst Pharmaceuticals Announces FDA Acceptance of the Supplemental New Drug Application for FIRDAPSE® October 13,...
Thursday, October 12, 2023   (0 Comments - view/add)
New Study Demonstrates Safety Shot Significantly Reduced Blood Alcohol Within 30 Minutes Compared to »
New Study Demonstrates Safety Shot Significantly Reduced Blood Alcohol Within 30 Minutes Compared to Control October...
Monday, October 9, 2023   (0 Comments - view/add)
Germfree Laboratories and AST Unite to Redefine Aseptic Fill-Finish Processing Technology »
Germfree Laboratories and AST Unite to Redefine Aseptic Fill-Finish Processing Technology Monday, 09 October 2023 13:...
Friday, October 6, 2023   (0 Comments - view/add)
Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft™ »
Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft™ October 06, 2023 09:00 ET| Source:  Ma...
Thursday, October 5, 2023   (0 Comments - view/add)
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Dru »
Oragenics to Acquire Odyssey Health’s Neurological Drug Technology Pipeline Including Concussion Drug Candidate Gai...
Wednesday, October 4, 2023   (0 Comments - view/add)
Aventa Genomics Announces Launch of Aventa FusionPlus, the First 3D Genomics Clinical Test for Patie »
Aventa Genomics Announces Launch of Aventa FusionPlus, the First 3D Genomics Clinical Test for Patients with Solid Cancers...
Monday, October 2, 2023   (0 Comments - view/add)
Zevra Therapeutics Announces Interim Data From The Phase 2 Clinical Trial Of KP1077 For Idiopathic H »
Zevra Therapeutics Announces Interim Data From The Phase 2 Clinical Trial Of KP1077 For Idiopathic Hypersomnia Octobe...
Wednesday, September 27, 2023   (0 Comments - view/add)
Omeza Announces New Tranche of Funding and Upcoming Q4 Clinical Activities »
Omeza Announces New Tranche of Funding and Upcoming Q4 Clinical Activities NEWS PROVIDED BY Omeza LLC&nb...
Tuesday, September 26, 2023   (0 Comments - view/add)
Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication »
Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult P...
Wednesday, September 20, 2023   (0 Comments - view/add)
Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1 »
Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 Long-Term Study of REL-1017 in Major Depressiv...
Monday, September 18, 2023   (0 Comments - view/add)
OrganaBio Approved as A Science Exchange and Scientist.com Partner »
OrganaBio Approved as A Science Exchange and Scientist.com Partner   September 18, 2023 01:23 PM Eastern D...
Thursday, September 14, 2023   (0 Comments - view/add)
First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi »
First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi First Wave to develop an...
Friday, September 8, 2023   (0 Comments - view/add)
Stuart Therapeutics Announces Issuance of U.S. Patent Covering Ophthalmic Anterior Segment Disorders »
Stuart Therapeutics Announces Issuance of U.S. Patent Covering Ophthalmic Anterior Segment Disorders Stuart Expands it...
Thursday, September 7, 2023   (0 Comments - view/add)
New Study Describes First, Functional Human Model to Investigate Opiate Overdose and Recovery »
New Study Describes First, Functional Human Model to Investigate Opiate Overdose and Recovery September 07, 2023 02:...
Wednesday, September 6, 2023   (0 Comments - view/add)
American TelePhysicians and LANGaware Collaborate to Revolutionize Early Diagnosis of Cognitive and »
American TelePhysicians and LANGaware Collaborate to Revolutionize Early Diagnosis of Cognitive and Mental Health Diseases...
Tuesday, September 5, 2023   (0 Comments - view/add)
Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector™ »
axogen, inc. announces full launch of axoguard ha+ nerve protector™ September 05, 2023 ALACHUA, Fla. and TAMPA, F...
Tuesday, September 5, 2023   (0 Comments - view/add)
Exactech Debuts New Primary Knee System: TriVerse™ »
Exactech Debuts New Primary Knee System: TriVerse™   September 05, 2023 09:00 AM Eastern Daylight Time G...
Tuesday, September 5, 2023   (0 Comments - view/add)
ILiAD Biotechnologies Reports First-ever Demonstration of Protection Against B. pertussis Colonizati »
ILiAD Biotechnologies Reports First-ever Demonstration of Protection Against  B. pertussis  Colonization in Phas...
Tuesday, August 22, 2023   (0 Comments - view/add)
Protean BioDiagnostics Partners with Travera to Support Advanced Carcinoma Patients and Their Physic »
Protean BioDiagnostics Partners with Travera to Support Advanced Carcinoma Patients and Their Physicians Protean BioDi...
Tuesday, August 15, 2023   (0 Comments - view/add)
Biostax Corp Announces the FDAs Acceptance of Three Investigational New Drug Applications (IND) Tran »
Biostax Corp Announces the FDAs Acceptance of Three Investigational New Drug Applications (IND) Transfers for JKB-122 for...
Thursday, August 10, 2023   (0 Comments - view/add)
ChromaCode and Protean BioDiagnostics Establish Strategic Partnership to Introduce a HDPCR-based NSC »
ChromaCode and Protean BioDiagnostics Establish Strategic Partnership to Introduce a HDPCR-based NSCLC Assay in the U.S....
Thursday, August 10, 2023   (0 Comments - view/add)
Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficac »
Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a T...

Displaying page 6 of 27
1  |  2  |  3  |  4  |  5  |  6  |  7  |  8  |  9  |  10  |  11  >   >>   >| 

About BioFlorida

BioFlorida is the voice of Florida's life sciences industry, representing 8,600 establishments and research organizations in the BioPharma, MedTech, Digital Health and Health Systems that collectively employ nearly 107,000 Floridians. Source: TEConomy/BIO (released 2022)